EcoDrugPlus

Aldo-Keto Reductase Family 1 Member B1-Like

Ensembl ID : ENSOKIG00005043395
Gene Symbol: LOC109879099
3 Cross references
340 Possible Orthologues:

Aldo-Keto Reductase Family 1, Member B1 (Aldose Reductase), Tandem Duplicate 2

Ensembl ID : ENSOKIG00005043530
Gene Symbol: AKR1B1.2
1 Cross references
331 Possible Orthologues:

Alpha Glucosidase

Ensembl ID : ENSOKIG00005043144
Gene Symbol: GAA
1 Cross references
226 Possible Orthologues:

Alpha Glucosidase

Ensembl ID : ENSOKIG00005044194
Gene Symbol: GAA
3 Cross references
226 Possible Orthologues:

Alpha-1a Adrenergic Receptor

Ensembl ID : ENSOKIG00005039100
Gene Symbol: LOC109880662
3 Cross references
185 Possible Orthologues:

Alpha-1a Adrenergic Receptor-Like

Ensembl ID : ENSOKIG00005015848
Gene Symbol: LOC109895108
3 Cross references
196 Possible Orthologues:

Alpha-1a Adrenergic Receptor-Like

Ensembl ID : ENSOKIG00005005311
Gene Symbol: LOC109871907
3 Cross references
196 Possible Orthologues:

Alpha-Synuclein

Ensembl ID : ENSOKIG00005006168
Gene Symbol: LOC109877861
2 Cross references
183 Possible Orthologues:

Amiloride-Sensitive Amine Oxidase [Copper-Containing]

Ensembl ID : ENSOKIG00005033718
Gene Symbol: LOC109899365
3 Cross references
225 Possible Orthologues:

Amiloride-Sensitive Amine Oxidase [Copper-Containing]-Like

Ensembl ID : ENSOKIG00005036177
Gene Symbol: LOC109908743
3 Cross references
225 Possible Orthologues:

Amyloid Beta Precursor Protein

Ensembl ID : ENSOKIG00005007296
Gene Symbol: APP
3 Cross references
197 Possible Orthologues:

Amyloid Beta Precursor Protein

Ensembl ID : ENSOKIG00005016232
Gene Symbol: APP
3 Cross references
196 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).